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Abstract
Introduction: Helicobacter pylori resistance to antibiotics is steadily increasing
and multidrug-resistant strains are common and difficult to eliminate,
mainly in countries where bismuth, tetracycline, furazolidone, and rifabutin
are unavailable.
Aim: To evaluate the efficacy and safety of a triple therapy with proton-
pump inhibitor (PPI), amoxicillin, and doxycycline in patients with multi-
drug-resistant H. pylori.
Patients and Methods: This prospective study involved 16 patients (13
females; mean age – 50  11.3 years) infected by H. pylori with known
resistance to clarithromycin, metronidazole, and levofloxacin, but suscepti-
bility to amoxicillin and tetracycline. All patients were previously submitted
to upper endoscopy with gastric biopsies for H. pylori culture and susceptibil-
ity testing by Etest. Mutations in 23S rRNA and gyrA genes were determined
by real-time PCR. A 10-day eradication regimen with PPI (double-standard
dose b.i.d.), amoxicillin (1000 mg b.i.d.), and doxycycline (100 mg b.i.d.)
was prescribed after pretreatment with PPI during 3 days. Eradication
success was assessed by 13C-urea breath test 6–10 weeks after treatment.
Compliance and adverse events were determined through phone contact
immediately after treatment and specific written questionnaires.
Results: Only one patient did not complete treatment due to adverse events.
Another four patients experienced mild side effects not affecting compliance.
The control 13C-urea breath test was positive in all patients. Per-protocol
and intention-to-treat eradication rates were 0%.
Conclusions: Although safe, a triple-therapy protocol with high-dose PPI,
amoxicillin, and doxycycline is useless for multidrug-resistant H. pylori
eradication.
Helicobacter pylori (H. pylori) infection is a recognized
worldwide problem affecting an estimated 50% of the
global population [1,2]. H. pylori is associated with mul-
tiple gastric pathologies, including gastritis, gastroduo-
denal ulcer disease, gastric adenocarcinoma, and
mucosa-associated lymphoid tissue (MALT) lymphoma
[3].
There are specific indications for H. pylori eradication,
and the empiric triple treatment comprising proton-
pump inhibitors (PPIs), clarithromycin, and amoxicillin
or metronidazole is universally accepted since it was
proposed at the first Maastricht conference [2,4]. How-
ever, the efficacy of standard triple therapy has
decreased in the last decades and is now inferior to 80%
in several countries [2,5]. This is related to increased
antibiotic consumption and increased resistance of
H. pylori to clarithromycin [6]. When empiric treatments
fail, the remaining options become more limited because
H. pylori can acquire resistance to some antibiotics, spe-
cially clarithromycin, levofloxacin, and metronidazole,
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which no longer should be used in subsequent treat-
ments. Metronidazole is probably the exception because
resistance to this drug can be partially overcome by
increased dose and duration of treatment [7]. Strains of
H. pylori that are resistant to at least two antibiotics are
defined as multidrug resistant [8].
H. pylori is naturally not susceptible to multiple antibi-
otics including vancomycin, trimethoprim, sulfonamides,
glycopeptides, cefsulodin and polymyxins [9,10]. Besides
amoxicillin, clarithromycin, and metronidazole, the other
antibiotics that can be used in H. pylori eradication are
tetracyclines, fluoroquinolones (mainly levofloxacin),
rifampins, fosfomycin, other 5-nitroimidazoles, and nitro-
furans [9].
Doxycycline is a tetracycline analogue and may be
an alternative. This antibiotic has bacteriostatic proper-
ties through the inhibition of bacterial protein synthe-
sis. “In vitro” susceptibility of H. pylori to doxycycline
had already been demonstrated, and different treat-
ments with this antibiotic were previously presented
but the results were heterogeneous [8,11–20].
Although it is possible to achieve a 99.5% cumula-
tive H. pylori eradication success with an overall strategy
of sequential empiric therapies, it is still recommended
to perform gastric biopsies and antibiotic susceptibility
testing after failure of two successive treatments [2,21].
Unfortunately, there are countries where multiple sec-
ond- or third-line drugs currently used for H. pylori
treatment are unavailable. Multiple resistant strains are
almost untreatable in such circumstances and adapted
therapies, even including doxycycline, are acceptable
alternatives.
The aim of this study was to evaluate the efficacy
and tolerability of a doxycycline-containing triple ther-
apy in patients infected by H. pylori strains with known
resistance to clarithromycin, metronidazole, and levo-




In this single-center study, consecutive patients infected
by H. pylori with known resistance to clarithromycin,
metronidazole and levofloxacin, but susceptibility
to amoxicillin and tetracycline, were prospectively
included. Exclusion criteria were: age under 18 years;
pregnancy; lactating and/or fertile women who were
not using safe contraceptive methods; history of
allergy/hypersensitivity to any antibiotic or PPI; previ-
ous gastric malignancy and/or gastric surgery; current
use of anticoagulants; marked thrombocytopenia;
systemic severe disease (hepatic, cardiorespiratory or
renal disease; uncontrolled diabetes; active malignant
diseases, coagulopathies); use of antibiotics in the last
4 weeks; use of PPI in the last 2 weeks.
For all patients, prior eradication treatments and
antibiotic consumption in the last 12 months were
recorded. Information about age, gender, ethnic back-
ground, body mass index, local of residence, education
level, alcohol and tobacco consumption, and history of
frequent infections was also obtained and registered.
Following previous recommendations, this proof-of-
concept study was designed for initial inclusion of 30
patients and would stop if a cure rate of 97% was
achieved or if six failures occurred [22].
Study Design
All patients have previously received one or more failed
eradication attempts. They were then submitted to upper
endoscopy with biopsies in the antrum and the corpus
that were immediately placed in independent containers
of adequate transport media – Portagerm pylori
(bioMerieux, Portugal) – at 4 °C, and sent to microbiol-
ogy laboratory. Urease test and Gram staining of a smear
prepared from the biopsy specimen were performed to
confirm the presence of H. pylori. After manual grinding
with disposable material, the samples were distributed
directly in agar pylori (bioMerieux Portugal, Linda-A-
Velha, Portugal). Cultures were incubated for a mini-
mum of 72 hours and a maximum of 10 days at 37 °C
under microaerophilic conditions, produced with H2-
CO2-generating packs (GENbag; bioMerieux, Portugal).
H. pylori isolates were identified by colony morphology,
characteristic spiral morphology on Gram staining, and
positive catalase, urease, and oxidase tests.
Minimum inhibitory concentrations (MIC) for amox-
icillin, clarithromycin, metronidazole, levofloxacin, and
tetracycline were determined by Etest (bioMerieux,
Portugal). In order to minimize variations in the results,
Hp ATCC 43504 strain was used for quality control of
the susceptibility assay and a different microbiologist
repeated all tests. MIC values were expressed in lg/mL,
and strains were considered resistant to amoxicillin,
clarithromycin, metronidazole, levofloxacin, and tetra-
cycline at MIC >0.5, >1, >8, >1, and >1 lg/mL,
respectively. MIC values were established according to
the data available in 2009, including the CLSI break-
points [9,23–28].
DNA extraction from pure culture of H. pylori was
performed with a special extraction kit (QIAamp DNA
Mini Kits; QIAGEN, Izasa Portugal, Carnaxide, Portu-
gal) according to the manufacturer’s instructions. Point
mutations in 23S rRNA gene, conferring resistance to
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clarithromycin, and in the quinolone resistance-deter-
mining region of the gyrA gene, mainly involving
amino acid substitutions at amino acid 87 and amino
acid 91, were detected by real-time PCR using a Light-
Cycler device, as previously described [25,29].
Eradication Therapy and Efficacy Assessment
All patients were prescribed with the following treat-
ment: pantoprazole (80 mg b.i.d) for the first 3 days
followed by a 10-day eradication regimen with pantop-
razole (80 mg b.i.d.), amoxicillin (1000 mg b.i.d.), and
doxycycline (100 mg b.i.d.).
After detailed explanation of the therapy and poten-
tial secondary effects to the patients on the day of clini-
cal observation, they were given a diary to record all
administrations, side effects, and symptoms during ther-
apy. Patients were contacted by phone immediately
after treatment to register the compliance as well as all
potential symptoms or adverse events. They were sub-
mitted to 13C-urea breath test (UBT) 6–10 weeks after
ending the treatment, to assess H. pylori status. At this
time, the compliance was, once more, confirmed by
counting the tablets returned by the patient. Poor com-
pliance was assumed if <80% of the drugs were taken.
The patients also returned the diaries fulfilled during
treatment, and they were asked to assess the tolerance
and efficacy of this therapeutic regimen in symptomatic
improvement through visual scales from 0 to 10 (0 – no
tolerance at all and 10 – excellent tolerance; 0 – no effi-
cacy and 10 – full efficacy). Adverse events were scored
as mild, moderate, or severe according to their influence
in daily activities (daily activities not limited, limited in
some extent, or not possible at all, respectively) and the
need to discontinue treatment. The scoring system was
based on the one proposed by de Boer et al. [30], with
minor modifications. All along the study the patients
had direct telephonic access to an investigator, in order
to resolve all doubts and problems that eventually
occurred.
No antibiotics or antisecretory drugs were allowed, 4
and 2 weeks, respectively, before the UBT. It was con-
sidered positive if the d-value over baseline was ≥4&.
Statistics
Categorical variables were presented with their relative
and absolute values, and quantitative ones were
expressed as mean  standard deviation. Analysis of
H. pylori eradication success was performed on an
intention-to-treat (includes all eligible patients enrolled
in the study, regardless of compliance with the study
protocol; patients with unavailable data are assumed to
have been unsuccessfully treated) and per-protocol
(includes only patients with good compliance and with
all data evaluable at the end of treatment) basis. If pos-
sible, univariate and multivariate analyses would be
performed to evaluate the association of different vari-
ables with effectiveness of treatment.
Ethical Considerations
The study was approved by the ethical committee of
our hospital and the Faculty of Medicine and per-
formed in accordance with the Declaration of Helsinki,
the International Conference on Harmonisation Good
Clinical Practice Guidelines, and applicable local laws
and regulations. Signed informed consent was obtained
from each patient.
Results
Sixteen patients, including 13 women and three men,
with an average age of 50 years, were included. Demo-
graphic and clinical characteristics of these patients are
presented in Table 1. The mean number of eradication
attempts was 2.8  1.3 (range: 1–6), and the drugs
used during these treatments are summarized in
Table 2.
Table 1 Demographic and clinical characteristics of the patients
Variables n = 16









Indication(s) for H. pylori eradication (%)
Dyspepsia 12 (75)




Iron-deficient anemia 2 (12.5)
Peptic ulcer 1 (6.3)
BMI (Kg/m2) 27.2  3.9 (range 19.6–33.8)
Smoking (%) 5 (31.3)
Alcohol consumption (%) 4 (25)
History of frequent infections (%) 2 (12.5)
Antibiotic consumption in the
last 12 months (%)
8 (50)
BMI, body mass index; GERD, gastroesophageal reflux disease; PPI,
proton-pump inhibitor.
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Antibiotic susceptibility testing confirmed resistance
to clarithromycin, metronidazole, and levofloxacin in
all 16 isolates. Genotyping revealed mutations in 23S
rRNA in 15 cases (93.8%) and mutations in gyrA in 14
(87.5%).
Adverse effects (Table 3) were reported in five
patients (31.2%), being mild in four and severe in one.
This patient suspended therapy prematurely and was
excluded from per-protocol analysis.
Patients’ median assessment of the treatment in
terms of tolerance and efficacy, according to a visual
scale, was 8 (range: 2–10) and 6 (range: 2–9), respec-
tively.
Control UBT was positive in all the 16 patients. Per-
protocol and intention-to-treat eradication rates were
0%.
Discussion
H. pylori eradication may fail in up to 40% of cases
after second-line regimens. In clinical practice we are
frequently confronted with patients for whom two or
more treatment attempts were unsuccessful [8]. Our
patients had a mean of 2.8 eradication failures before
inclusion. After failure of two consecutive treatments
including clarithromycin and metronidazole, at least
single and frequently double resistance of H. pylori is
common [31].
Salvage treatments should be determined according
to the results of culture and susceptibility tests or, as
alternative, to the results of molecular methods
allowing detection of resistance to clarithromycin and
levofloxacin. However, culture implies general endo-
scopic risks, is expensive, labor-intensive, not always
available on a routine basis, and its sensitivity is not
100% [32]. Molecular methods are also not accessible
in all centers and only two drugs can be tested. On the
other hand, the choice of drugs for salvage therapy
depends on which treatments were formerly used
because re-treatment with the same drugs is not recom-
mended except for amoxicillin [31]. In our study, clari-
thromycin and levofloxacin were already used in
93.7% of patients and nitroimidazoles in 75%. Unfortu-
nately, antibiotic consumption in Portugal is very high.
A detailed history of previous infections and antibiotic
consumption allowed us to determine that even the
patients without prior H. pylori eradication attempts
had once used macrolides, fluoroquinolones, and/or ni-
troimidazoles for the treatment of respiratory and/or
gynecological infections. So, all 16 patients had past
history of clarithromycin, levofloxacin, and nitroimidaz-
oles consumption and H. pylori resistance to all of them
was expected. Also, as previously reported, there were
no cases of resistance to amoxicillin, even after multiple
failed treatments using this drug. New therapeutic regi-
mens with clarithromycin, nitroimidazoles, or levoflox-
acin were not recommended. The only exception could
be, eventually, quadruple therapy containing bismuth,
PPI, tetracycline, and metronidazole because this regi-
men can overcome, at least partially, the negative effect
of metronidazole resistance [7,8,31].
In countries like Portugal, where bismuth, tetracy-
cline, furazolidone are unavailable and rifabutin use is
very restricted, it is almost impossible to delineate a sal-
vage therapy after use of metronidazole/tinidazole, clar-
ithromycin, and levofloxacin. An alternative to
tetracycline HCl could be doxycycline that belongs to
the same therapeutic group. Heep et al., found no cases
of H. pylori resistance to doxycycline in isolates from
patients in whom one or more therapies had failed, but
another work identified a resistance rate of 33.3%
[12,33].
Doxycycline, a synthetic antibiotic developed in
1967, theoretically would have some advantages over
tetracycline: half-life of 18 hours allowing one or two
daily administrations instead of four; better tissue pene-
tration; better absorption with food; predominantly
extrarenal excretion; reduced gastric chelation with
bismuth if this drug is used concomitantly [11,34,35].
Different treatment regimens for H. pylori eradica-
tion containing doxycycline were already published.
However, the proposed combination of drugs, treatment
duration, and final results were very heterogeneous
and difficult to compare. Eradication rates on intention-
to-treat protocol differed from 36 to 91%, being higher
Table 2 Drugs used in the previous eradication attempts
Drugs n = 16
Amoxicillin (%) 16 (100)
Clarithromycin (%) 15 (93.7)
Nitroimidazoles (%) 12 (75)
Metronidazole (%) 6 (37.5)
Tinidazole (%) 4 (25)
Metronidazole and tinidazole (%) 2 (12.5)
Levofloxacin (%) 15 (93.7)
Table 3 Reported adverse events
Adverse events n = 16
Abdominal pain (%) 4 (25)
Nausea (%) 3 (18.8)
Headache (%) 1 (6.3)
Severe diarrhea and vomiting (%) 1 (6.3)
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for quadruple regimens [8,11–19]. Treatment with PPI,
amoxicillin, and doxycycline, although suboptimal,
would allow eradication of H. pylori in, at least, one-
third of patients. Given all difficulties with rescue regi-
mens in our country, we tried to optimize therapy
using pretreatment and high-dose PPI.
Proton-pump inhibitors influence the efficacy of
H. pylori eradication, and its action depends on the
CYP2C19 genotype. Theoretically, standard PPI doses
would be insufficient in extensive metabolizers to
accomplish enough pH inhibition for efficient antibiotic
activity in gastric mucosa, determining lower eradica-
tion rates [36]. Westerners, as our patients, are gener-
ally rapid metabolizers and might benefit from higher
PPI dosages [37]. Graham et al., also observed that the
treatment success was ~5% higher when the PPI was
given at twice the standard dose, and the last Maas-
tricht IV/Florence consensus established that there is
indirect and direct evidence that high-dose PPI can
improve the cure rates of H. pylori treatment [2,5]. A
recent meta-analysis also assumed that increasing PPI
dose above the current standards could improve cure
rates of H. pylori therapy [38]. Because we had no pos-
sibility to determine CYP2C19 genotype, we decided
that it was acceptable to use high-dose PPI.
Pretreatment with PPI is controversial, and a meta-
analysis showed no differences in eradication rates
between patients with or without pretreatment [39].
Some older data suggested that pretreatment with a PPI
before the administration of H. pylori eradication ther-
apy might decrease treatment efficacy, but the meta-
analysis and more recent articles do not confirm this
information [39–43]. Given the special circumstances of
our patients, we decided that such a strategy, albeit a
potential confounding factor, could be beneficial.
However, our eradication rate was 0% with this
regimen. This was rather unexpectable given the
results of previous published series and the in vitro
susceptibility to amoxicillin and tetracycline. With the
simple combination of high-dose PPI and amoxicillin,
we were expecting, at least, a modest rate of eradica-
tion, according to the results of dual therapy [41]. Side
effects and no compliance were not responsible for
such a failure because only one patient experienced
severe adverse events and had to suspend treatment.
Probably, as some authors already stated, there is an
antagonistic effect between these two antibiotics,
because doxycycline has a bacteriostatic action and
amoxicillin has a bactericidal one. The bacteriostatic
effect of doxycycline inhibits ribosomal protein synthe-
sis and may prevent binding of amoxicillin to its
bacterial cell wall target [13,16]. Doxycycline in the
gastric lumen can also interfere with topical action of
amoxicillin and vice versa [13]. On the other side,
some authors defend that when we perform suscepti-
bility tests we must use the compound indicated and,
for example, we cannot substitute tetracycline HCl by
doxycycline [2]. In fact, we did not test susceptibility
of H. pylori isolates to doxycycline, but other authors
defended that metronidazole and tetracycline can be
replaced by tinidazole and doxycycline, respectively
[27]. Another possibility is that the higher dosage of
PPI was ineffective in maintaining pH consistently
above 6 and more important than give higher doses
two times a day would be to increase the frequency of
administration. The type of PPI could also be impor-
tant. A recent meta-analysis demonstrated that the
degree of acid inhibition is not the same for all PPIs.
Based on the mean 24-hour gastric pH, the relative
potencies of esomeprazole and rabeprazole are higher
than the ones for omeprazole and pantoprazole [44].
As previously discussed, instead of the traditional
40 mg b.i.d., we administered 80 mg of pantoprazole
b.i.d. Because PPIs have better efficacy in H. pylori-
infected patients, these dosages were, theoretically,
sufficient. Even so, we assume that higher doses of
pantoprazole or even new-generation PPIs such as rab-
eprazole and/or esomeprazole would be acceptable and
eventually more effective [45].
We can also speculate that drug dosage or treatment
duration was inadequate. Previous studies with doxycy-
cline had durations from 7 to 14 days, and with few
exceptions, this antibiotic was administered two times a
day. In our study, we tried to optimize compliance and
we decided that all drugs would be administered twice
daily during 10 days, with PPI pretreatment for 3 days
(total duration of treatment – 13 days). Doxycycline
has a long half-life, and two daily administrations are
enough, but for PPI and amoxicillin four daily adminis-
trations would probably be better. However, albeit we
applied a simplified therapeutic regimen, with high
compliance rates, no H. pylori eradication was achieved
in our study. So, it is questionable if it is worthwhile to
try a more complicated regimen, with four daily admin-
istrations of PPI and amoxicillin and twice a day doxy-
cycline, for 14 days. This therapy would be eventually
more effective but with increased pill burden and sec-
ondary effects, compromising patient tolerability and
adherence.
Besides the problems already discussed, our
study has some other limitations: a small number of
patients; the use of Etest to determine susceptibility to
metronidazole; lack of molecular methods to confirm
metronidazole resistance.
The small number of patients is easily explained by
our study design. We consecutively enrolled 16
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patients, but with the first six eradication failures, we
prematurely finished inclusion.
Metronidazole susceptibility testing by Etest can be
overestimated by 10–20% in comparison with determi-
nation by the agar dilution method, and both methods
are not sufficiently reliable to determine susceptibility
of H. pylori to this antibiotic because they lack repro-
ducibility [24]. We tried to overcome this problem by
using a control strain and repeating the test by another
microbiologist. We must also remember that all patients
had already taken nitroimidazoles and this can explain
the presence of H. pylori resistance to nitroimidazoles.
Finally, the molecular methods confirmed the pres-
ence of 23S rRNA and gyrA mutations in 93.7 and
87.5% of H. pylori isolates, respectively. These results
are perfectly plausible because the methodology used
detected the most common mutations. The molecular
mechanisms of metronidazole resistance in H. pylori are
more complex and there are no easily implementable
methods to detect such modifications [9,46].
The main question now is what alternative can
we offer to our patients as we are dealing with triple-
resistant strains. In ideal conditions there would be five
options: a triple therapy with rifabutin; quadruple ther-
apy with tetracycline or amoxicillin and furazolidone;
quadruple treatment regimen with tetracycline and
metronidazole; concomitant or hybrid therapy; and
dual therapy with high doses of PPI and amoxicillin.
Given the limitations for our country, only the last two
can be considered.
Hybrid and concomitant therapies, including PPI,
amoxicillin, clarithromycin, and metronidazole, are
recently proposed therapies. Apparently, these regi-
mens, due to prolonged duration of amoxicillin admin-
istration, have high efficacy in the treatment of
H. pylori strains harboring dual resistance to clarithro-
mycin and metronidazole. However, further studies in
populations with different levels of prevalence of clari-
thromycin and metronidazole resistance are needed to
assess the efficacy of the new regimen [3,47].
The old-fashioned but recently revived dual therapy
with PPI and amoxicillin for 14 days could be a good
option because it is easily available and, in patients
with previous failed treatments, its efficacy is compara-
ble to the one of rifabutin-based therapy [48]. Use of a
new-generation PPI and 4 daily administrations of this
drug and amoxicillin seem to be of major importance to
achieve higher eradication rates [37,45,49]. A trial per-
formed in another South European country revealed
disappointing results with dual therapy [50]. In this
study, both drugs were administered two and not four
times a day and that probably could have influenced
the final results.
Conclusion
A triple therapy including PPI in high doses, amoxicil-
lin, and doxycycline, although well tolerated, is useless
for the eradication of multidrug-resistant H. pylori.
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